Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells

Haematologica

Volumn 94, Issue 11, 2009, Pages 1590-1594

  Langenkamp, Ulrich ^a   Siegler, Uwe ^a   Jörger, Simon ^a   Diermayr, Stefan ^a   Gratwohl, Alois ^a   Kalberer, Christian P ^a   Wodnar Filipowicz, Aleksandra ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Acute leukemia; Immunotherapy; Natural killer; Stem cells

Indexed keywords

HLA ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CD34+CD38 STEM CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYSIS; NATURAL KILLER CELL; STEM CELL TRANSPLANTATION;

HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, NATURAL KILLER CELL;

EID: 70449449380     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.005967     Document Type: Article

References (24)

1. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres- Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648 (Pubitemid 24067706)
2. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007;13:470-481 (Pubitemid 350086980)
3. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640
4. Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002;23:438-444 (Pubitemid 35015187)
5. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-440 (Pubitemid 47026866)
6. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003;3:108-122 (Pubitemid 37328689)
7. Lanier LL. On guard--activating NK cell receptors. Nat Immunol 2001;2:23-27
8. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790
9. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-1396 (Pubitemid 36988048)
10. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005;105:3615-3622 (Pubitemid 40628208)
11. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor-ligand interactions in the natural killermediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005;105:2066-2073 (Pubitemid 40731793)
12. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NKcell lines with single KIR-HLA class I specificities. Blood 2008;111:1428-1436 (Pubitemid 351213430)
13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737 (Pubitemid 27298715)
14. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-743 (Pubitemid 39023306)
15. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007;25:1315-1321 (Pubitemid 350076512)
16. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005;19:2215-2222 (Pubitemid 41741617)
17. Bridenbaugh S, Kenins L, Bouliong- Pillai E, Kalberer CP, Shklovskaya E, Gratwohl A, et al. Clinical stem-cell sources contain CD8+CD3+ T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells. Blood 2008;111:1735-1738 (Pubitemid 351213466)
18. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008;28:571-580
19. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006;66:3959-3962
20. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, Lopez-Vazquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008;14:179-189
21. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLLAF9 acute myeloid leukemia. Cancer Cell 2006;10:257-268 (Pubitemid 44512188)
22. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005;65:2537-2541 (Pubitemid 40490047)
23. De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, et al. Histone deacetylase inhibitor valproic acid enhances the cytokineinduced expansion of human hematopoietic stem cells. Cancer Res 2005;65:1505-1513 (Pubitemid 40270180)
24. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007;7:329-339 (Pubitemid 46674487)